Astorg is moving quickly to turn Solabia into a scaled European platform in natural active ingredients and diagnostics. In a span of roughly two to five months, the Astorg-backed group has completed three acquisitions: Mibelle Biochemistry in Switzerland (February), Seqens’ botanical active ingredients and in vitro diagnostics activities in France, and Xebios Diagnostics Group across Germany and the Netherlands. Financial terms were not disclosed.
The pace matters. These are Solabia’s first acquisitions since Astorg invested in October 2025, and they land as a coordinated package rather than opportunistic one-offs. Post-deal, Solabia’s revenue is reported at around EUR 250 million, giving the group more scale to support R&D, manufacturing leverage, and a broader go-to-market across end markets that include cosmetics, pharma, and biotech.
What Astorg is building
The strategic logic reads as a classic mid-market playbook: expand the product set, deepen technical capabilities, and tighten control over supply and manufacturing in areas where customers care about performance, quality, and continuity.
Two threads link the acquisitions:
- Natural active ingredients: strengthening botanical extraction and ingredient capabilities, while extending geographic reach.
- Diagnostics: expanding manufacturing footprint and adding microbiological testing capabilities, with room for cross-selling across regulated applications.
Solabia’s acquisitions broaden its presence across Switzerland, France, Germany, and the Netherlands, improving coverage in key European markets and adding assets that appear complementary rather than overlapping.
Deal-by-deal: supply security and footprint expansion
Seqens (France) is the most strategically interlocking asset set. The acquisition of Seqens’ botanical active ingredients is positioned as reinforcing Solabia’s botanical capabilities and, importantly, securing critical raw material supply for its diagnostics activities. Seqens’ facility in Limoges brings advanced botanical extraction, which supports supply security for both cosmetics and diagnostics applications.
Xebios Diagnostics Group (Germany/Netherlands) expands Solabia’s diagnostics footprint and increases vertical integration. Xebios enhances the manufacturing base across France, Germany, and the Netherlands, and strengthens Solabia’s position in microbiological diagnostics for water, food, cosmetics, and clinical samples in the German and Dutch markets. The company also adds high-performance microbiology solutions that can complement Solabia’s existing portfolio and create cross-sell pathways.
Mibelle Biochemistry (Switzerland) extends Solabia’s geographic reach and technical expertise within active ingredients, reinforcing the group’s ambition to scale in natural actives alongside diagnostics.
Across the three transactions, the stated benefits are consistent: greater scale, expanded technical expertise, enhanced R&D and innovation capacity, and stronger global distribution.
Integration is now the main variable
With three acquisitions completed in rapid succession, execution risk shifts from sourcing to integration. The strategic intent is clear, but several integration questions will determine whether Solabia captures the upside:
- Operating model and systems: Can Solabia standardise quality systems, regulatory documentation, and ERP processes across a multi-country footprint without slowing customer response times?
- Manufacturing and supply chain: The Seqens Limoges site and Xebios’ manufacturing base suggest a push toward tighter control. The key question is how quickly procurement, production planning, and quality management can be harmonised to deliver tangible service-level improvements.
- Commercial coordination: Cross-selling is often promised and rarely frictionless. Aligning account ownership, distributor strategies, and technical sales support across cosmetics, pharma, biotech, and diagnostics end markets will be decisive.
- Leadership bandwidth: Three integrations in a few months tests management depth. Clear governance and integration sequencing will matter as much as the asset quality.
Why this is a market signal
The deal cluster fits a with-trend pattern in European specialty ingredients and diagnostics: platforms are using M&A to add capabilities, secure inputs, and widen geographic coverage in niches where regulatory and technical requirements create durable barriers to entry.
Astorg’s approach here suggests confidence that customers will continue to value supply assurance and technical differentiation, and that scaled platforms can out-invest smaller peers in innovation and compliance.
What to watch next
- Integration milestones: systems harmonisation, quality alignment, and site-to-site operating cadence
- Evidence of cross-selling: bundled offerings and shared accounts across ingredients and diagnostics
- Manufacturing footprint optimisation: whether capacity and procurement synergies are realised without service disruption
- Further M&A: whether Solabia continues bolt-ons to deepen diagnostics or expand actives into new categories
- Management depth: any leadership additions to support a multi-country, multi-vertical platform